Palonosetron and netupitant for prevention of chemotherapy-induced nausea and vomiting

Article Type
Changed
Thu, 12/15/2022 - 18:04
Display Headline
Palonosetron and netupitant for prevention of chemotherapy-induced nausea and vomiting

The US Food and Drug Administration (FDA) recently approved NEPA, an oral fixed-dose combination of netupitant and palonosetron for treatment of chemotherapy-induced nausea and vomiting (CINV). Palonosetron is a pharmacologically distinct, best-in-class serotonin (5-hydroxytryptamine) type 3 (5-HT3) receptor antagonist, which prevents CINV during the acute phase (0-24 h) after administration of chemotherapy, and netupitant is a potent and selective neurokinin-1 (NK-1) receptor antagonist, which prevents CINV during both the acute and delayed (25-120 h) phases. The 2 agents have also been shown potentially to act synergistically in inhibiting NK-1 receptor activity.

 

Click on the PDF icon at the top of this introduction to read the full article.

 

Article PDF
Issue
The Journal of Community and Supportive Oncology - 13(4)
Publications
Topics
Page Number
128-130
Legacy Keywords
Palonosetron, netupitant, chemotherapy-induced nausea and vomiting, CINV
Sections
Article PDF
Article PDF

The US Food and Drug Administration (FDA) recently approved NEPA, an oral fixed-dose combination of netupitant and palonosetron for treatment of chemotherapy-induced nausea and vomiting (CINV). Palonosetron is a pharmacologically distinct, best-in-class serotonin (5-hydroxytryptamine) type 3 (5-HT3) receptor antagonist, which prevents CINV during the acute phase (0-24 h) after administration of chemotherapy, and netupitant is a potent and selective neurokinin-1 (NK-1) receptor antagonist, which prevents CINV during both the acute and delayed (25-120 h) phases. The 2 agents have also been shown potentially to act synergistically in inhibiting NK-1 receptor activity.

 

Click on the PDF icon at the top of this introduction to read the full article.

 

The US Food and Drug Administration (FDA) recently approved NEPA, an oral fixed-dose combination of netupitant and palonosetron for treatment of chemotherapy-induced nausea and vomiting (CINV). Palonosetron is a pharmacologically distinct, best-in-class serotonin (5-hydroxytryptamine) type 3 (5-HT3) receptor antagonist, which prevents CINV during the acute phase (0-24 h) after administration of chemotherapy, and netupitant is a potent and selective neurokinin-1 (NK-1) receptor antagonist, which prevents CINV during both the acute and delayed (25-120 h) phases. The 2 agents have also been shown potentially to act synergistically in inhibiting NK-1 receptor activity.

 

Click on the PDF icon at the top of this introduction to read the full article.

 

Issue
The Journal of Community and Supportive Oncology - 13(4)
Issue
The Journal of Community and Supportive Oncology - 13(4)
Page Number
128-130
Page Number
128-130
Publications
Publications
Topics
Article Type
Display Headline
Palonosetron and netupitant for prevention of chemotherapy-induced nausea and vomiting
Display Headline
Palonosetron and netupitant for prevention of chemotherapy-induced nausea and vomiting
Legacy Keywords
Palonosetron, netupitant, chemotherapy-induced nausea and vomiting, CINV
Legacy Keywords
Palonosetron, netupitant, chemotherapy-induced nausea and vomiting, CINV
Sections
Citation Override
JCSO 2015;13(4):128-130
Disallow All Ads
Alternative CME
Article PDF Media